Thierry Legon CEO, ASIT biotech - Paris May 03 2018
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Paris May 03 2018 Leader in Allergenic Peptide Immunotherapy
Thierry Legon
CEO, ASIT biotech
1
About ASIT biotech
Mission
To improve acceptance and compliance of allergy immunotherapy by developing
short course treatments based on innovative allergenic peptides
Main achievements
• Clinical efficacy of lead product in Grass Pollen Rhinitis confirmed in Phase 3
clinical study
• Validated technology platform to design, characterize, screen and produce
novel product candidates
• Ongoing design and screening of product candidates in House Dust Mite
Rhinitis and food allergy (peanuts, cow’s milk and egg white)
2
About ASIT biotech • ASIT biotech has dual market listing in Brussels (Belgium) and Paris (France) since May 2016 • Raised €73 million since inception (€23.4 million by IPO (2016) and €13.9 million by a private placement (2018)) • 26 active and motivated collaborators • Partnership with public and private internationally renowned institutions 3
Ever increasing number of allergic patients 4
Over 1 billion patients suffer today from Allergy and
over 4 billion in 2050
• Steadily increasing prevalence of allergic diseases
• More complex allergies with high morbidity leading to a heavy burden for
health care system
• 30 to 40% of the world population would be affected by one or more allergic
conditions
✓ Over 400 million patients suffer from Allergic Rhinitis
✓ Over 200 million patients suffer from Food allergies
✓ Over 300 million patients suffer from Asthma
World Allergy Week April 2011
EAACI
5
Allergic Rhinitis:
up to 400 million people worldwide
USA CHINA
EUROPE 1,6-43%
12-30%
23-30%
JAPAN USA Europe China Japan
9,1-37,5%
MIDDLE EAST
7,4-45,2% Population (M) 320 320 1379 127
Population with 43 73 TBD 38
Rhinitis (M)
Population with 24 25 TBD 9
severe Rhinitis (M)
LATIN AFRICA AUSRALIA
AMERICA 7,2-54,1% 12-41,3%
5,5-45,1%
Bauchau V & Durham SR Eur Respir J 2004; 24: 758-764
Katelaris, C.H. et al., 2012. Clinical and experimental allergy 42(2), pp.186–207
6 C.F., M. & Tong Janice S.C. Lin, 2015. European Academy of Allergy and Clinical Immunology, pp. 62–63.
Food Allergy:
more than 200 millions people worldwide
• 15 million of American, 17 million of
Europeans suffer from food allergy1
• Increasing prevalence in both
developed and developing countries2
• Peanut, cow’s milk and egg white
concern >74% children3
• Total annual food allergy management
cost estimate/child in the US: $ 4,184
1. Commins et al. 2016 and World Allergy Organization
2. Prescott et al. 2013
3. Scott et al. 2011
4. Gupta et al 2013
7
Allergy leads to symptoms
impairing quality of life
Reduced work
productivity
Eye symptoms
Asthma
Nasal Angiodema
symptoms
Sleep deprivation
Reduced
school performance
8
…if not threathening life…
Allergy: inappropriate immune response against
harmless substance
Th2
cell Allergens
B cell
2 1
1. First contact between allergen and IgE Antigen
mucosa synthesis Presenting
2. Allergen specific IgE antibody 3 cell
production
‒ Uptake & processing by
APC
‒ T- cell activation
‒ allergen specific IgE Mast cell Basophil
4 5
antibody production
3. Loading of allergen specific IgE on
mast cells Degranulation leading to
4. Bridging of the IgE by allergens histamine release
5. Allergic reaction
Eosinophils
Mast cell Basophil
recruitment and activation
9
Therapeutic options: Symptomatic vs Curative 10
Symptomatic drugs for allergic rhinitis
Interleukin specific Nonspecific immunosuppressors
blockers (mAb) Intranasal steroids
Allergic rhinitis & Mepolizumab (GSK)
Inhaled steriods
Leukotriene modifiers
Th2
Reslizumab (Teva)
asthma Benralizumab (AZ)
cell
• >95% of the market Dupilumab B cell Allergen
(Regeneron/Sanofi)
• daily intake during allergen
exposure (seasonal/perennial) IgE
synthesis
• no long-term effect IgE-specific blockers
(mAb) Antigen
Antihistamines
Zyrtec
• poor effectiveness in case of Presenting
cell Xyzal
low compliance Omalizumab Allegra
(Novartis/Genentech)
• $20 billion/year for Claritin
Mast cell Basophil
respiratory allergies Degranulation
leading to
histamines
release
Food allergy Mast cell Basophil
Eosinophils
• no registered drugs available recruitment
and
• food avoidance activation
• epinephrine injection
11Curative treatment: Allergy Immunotherapy
Sub-cutaneous Sublingual
12Allergy immunotherapy induces natural regulation of the
immune system and provides better symptoms reduction
Th2
cell
Allergen
-
IL-10 IL-35
1. Regulatory T and B cells IgG4 & IgA
B cell
2. Prevention of the seasonal synthesis 2
increase of IgE
+ 3
3. Induction of IgG4-associated
blocking antibodies leading
IgE synthesis
to clinical benefit during the Antigen
Treg Breg + 1
pollen season. Presenting
- cell cell Whole Allergens
4. Suppression of grass pollen- 2
cell
induced basophil activation
responsible for immediate
allergic response
4
-
Degranulation leading to
Mast cell Basophil histamine release
Eosinophils
Mast cell Basophil
recruitment and
activation
13Allergy immunotherapy market less than €1billion today
Year 1 Year 2 Year 3
COMPLIANCE
SCIT
SCIT 40-60
Subcutaneous
immunotherapy
Doctor visits < 25%
Daily
SLIT administration
Sublingual
immunotherapy
180 to 360 < 12.5%
days/year
3 year long cumbersome treatment
due to the use of whole allergen extracts
14Whole allergen extract limitations
Safety concerns: induction of histamine and proinflammatory substances
Efficacy concerns: delay in reaching the optimal balance between IgG4 and IgE
Allergen injectionsAllergen Injections
Symptoms
IgG and IgG4
IgE
Lymphocyte responses
6 months 2 years Time
15ASIT™ Innovative technology 16
ASIT+™ allergenic peptides allow short-course
treatment improving patient adherence and
compliance
ASIT biotech’s
Offer
4 visits
4 doctor visits in 3 weeks before each pollen season
17ASIT+TM unique safe and efficient active ingredients
Current Immunotherapy ASIT+TM Immunotherapy
Optimally-sized
Whole Allergens
natural allergenic peptides
Advantages
(1 – 10 kDa)
✓ Clinically effective
✓ Safety: SLIT > SCIT ASIT+TM Technology Platform ✓ Short course SCIT
✓ Include all the necessary
immunological information ✓ Real-life clinical efficacy during
✓ IgG4 and blocking antibodies grass pollen season confirmed
✓ Applicable to all allergies ✓ Fast onset of optimal
immunoregulation with blocking
Disadvantages antibodies induction
Increased AEs ✓ Applicable to all allergies
3 year treatment ✓ No need of adjuvant
Poor patient compliance ✓ Probable high patient adherence
Need of adjuvants and compliance
18ASIT+TM technology platform to design, characterize,
screen and produce novel product candidates
Extraction of Large proteins do not enter into the gel
allergens from particles
natural source => shorter pathway through the column.
ASIT+TM allergenic peptides enter into
the gel particles
Enzymatic => longer pathway through the column.
hydrolysis
Selection of
allergenic peptides
according to size
(1-10kDa)
19ASIT™ Clinical Development 20
ASIT biotech pipeline: achieved milestones
Pre-clinical Phase I Phase II Phase III
Q1 2017 - Positive phase III
Grass pollen
gp-ASIT+™
Q2 2017 - Positive Phase I/II
House dust mite
hdm-ASIT+™
Preclinical development program
Food
Peanut - Egg white - Cow’s milk
food-ASIT+™
21gp-ASIT+™ Positive Phase III clinical study (BTT009)
TRIAL # PATIENTS PRIMARY OBJECTIVE DESIGN
‒ 2:1 (active : placebo) ‒ Clinical efficacy during pollen ‒ Double-blind
‒ 93% retention rate: 512 season based on reduction in ‒ Placebo controlled
Phase III patients attended the the combined symptom- ‒ 67 centers in Europe
last visit medication score (CSMS)
• symptom and drug intake reduction statistically significant -15.5% during the peak and -17.9% over the
pollen season (pASIT™ mechanistic aspects
Prof. Mohamed Shamji
23Short Course treatment of Subcutaneous Peptide Hydrolysate from Lolium
Perenne suppresses Basophil Responses and induces IgG-associated
Blocking Antibodies: A RDPCT
Mohamed Shamji, PhD. CS. FAAAAI
Head, Immunomodulation and Tolerance Group
Director, Immune Tolerance Network Distributed Centre of Excellence for Allergy & Asthma, UK
Chair, Scientific Program Committee, European Academy, Allergy and Clinical Immunology
Associate Professor in Immunology and Allergy,
Allergy & Clinical Immunology, Imperial College London, UK
Media & Analyst Conference, Paris, France
Thursday, 3rd May, 2018
24Pathophysiology of Allergic Rhinitis and Mechanisms of AIT
ILC2
Natural exposure Cell CRTH2+ T cells
(Low-dose allergen) Allergen-
Th2 IL- Mast Cell Basoph specific IgE
Cell 9 il
Th
IL-
0
Tfh 5
Cell Eosinophi
Dendritic cells IL-4 l Plasma
(nasal CXCR5+ T cells IL-21 B Cell
mucosa) IL-13 Cel
l
Shamji et al., JACI
25Year 1 Year 2 Year 3 Compliance
SCIT
Subcutaneous
immunotherapy SCIT 40-60Characterisation of Peptide Hydrolysate from Lolium Perenne
(gpASIT+TM) and its ability to bind to IgE compared to Grass Pollen
extract
Reproducibility Basophil activation
Graph#8
CD63+ basophils [%]
80
IgE binding (%)
60
40
20
0
1e-4 0,001 0,01 0,1 1 10 100 1000
Concentration [µg/ml]
Concentration [µg/ml] Concentration [ng/mL]
4-P Fit: y = (A - D)/( 1 + (x/C)^B ) + D: A B C D R^2
Plot#2 (PROT 08J20 (1/3): Concentration vs %IN... -0.72 0.973 0.0861 95.7 0.999
Plot#4 (PROT 00597 (1/3): Concentration vs %IN... 4.86 0.835 0.0905 97.9 1 *p ≤ 0.05
Pollen proteins - batch 1
Plot#6 (PEP 00597 (1/3): Concentration vs %INHIB) -8.18 0.269 136 143 0.999
Plot#10 (PEP 08K05 (1/3): Concentration vs %INH... -12.8 0.227 497 170 0.998
**p ≤ 0.05
__________ Pollen proteins - batch 2 ***p ≤ 0.05
Weighting: Fixed
Pollen peptides - batch 1
Pollen peptides - batch 2 Shamji et al., JACI 2017
27Characterisation of Peptide Hydrolysate from Lolium Perenne
(gpASIT+TM) and its ability to bind to IgE compared to Grass Pollen
extract
Reproducibility Basophil activation
Graph#8
CD63+ basophils [%]
80
IgE binding (%)
60
40
20
0
1e-4 0,001 0,01 0,1 1 10 100 1000
Concentration [µg/ml]
Concentration [µg/ml] Concentration [ng/mL]
4-P Fit: y = (A - D)/( 1 + (x/C)^B ) + D: A B C D R^2
Plot#2 (PROT 08J20 (1/3): Concentration vs %IN... -0.72 0.973 0.0861 95.7 0.999
Plot#4 (PROT 00597 (1/3): Concentration vs %IN... 4.86 0.835 0.0905 97.9 1 *p ≤ 0.05
Pollen proteins - batch 1
Plot#6 (PEP 00597 (1/3): Concentration vs %INHIB) -8.18 0.269 136 143 0.999
Plot#10 (PEP 08K05 (1/3): Concentration vs %INH... -12.8 0.227 497 170 0.998
**p ≤ 0.05
__________ Pollen proteins - batch 2 ***p ≤ 0.05
Weighting: Fixed
Pollen peptides - batch 1
Pollen peptides - batch 2 Shamji et al., JACI 2017
28Characterisation of Peptide Hydrolysate from Lolium Perenne
(gpASIT+TM) and its ability to bind to IgE compared to Grass Pollen
extract
Reproducibility Basophil activation
Graph#8
CD63+ basophils [%]
80
IgE binding (%)
60
40
20
0
1e-4 0,001 0,01 0,1 1 10 100 1000
Concentration [µg/ml]
Concentration [µg/ml] Concentration [ng/mL]
4-P Fit: y = (A - D)/( 1 + (x/C)^B ) + D: A B C D R^2
Plot#2 (PROT 08J20 (1/3): Concentration vs %IN... -0.72 0.973 0.0861 95.7 0.999
Plot#4 (PROT 00597 (1/3): Concentration vs %IN... 4.86 0.835 0.0905 97.9 1 *p ≤ 0.05
Pollen proteins - batch 1
Plot#6 (PEP 00597 (1/3): Concentration vs %INHIB) -8.18 0.269 136 143 0.999
Plot#10 (PEP 08K05 (1/3): Concentration vs %INH... -12.8 0.227 497 170 0.998
**p ≤ 0.05
__________ Pollen proteins - batch 2 ***p ≤ 0.05
Weighting: Fixed
Pollen peptides - batch 1
Pollen peptides - batch 2 Shamji et al., JACI 2017
29Hypotheses - 3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne (LPP, gpASIT+TM) is associated with reduction in CSMS and RTSS during the peak and throughout the entire pollen season. - gpASIT+TM immunotherapy but not placebo blunts the seasonal increases of sIgE - gpASIT+TM immunotherapy but not placebo treatment suppresses grass pollen- induced basophil hyperesponsivess and basophil reactivity. - A short-course of gpASIT+TM immunotherapy induces IgG4-associated blocking antibodies that conferred clinical benefit during the pollen season and supresses pathogenic T cell responses. 30
Hypotheses - 3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne (LPP, gpASIT+TM) is associated with reduction in CSMS and RTSS during the peak and throughout the entire pollen season. - gpASIT+TM immunotherapy but not placebo blunts the seasonal increases of sIgE - gpASIT+TM immunotherapy but not placebo treatment suppresses grass pollen- induced basophil hyperesponsivess and basophil reactivity. - A short-course of gpASIT+TM immunotherapy induces IgG4-associated blocking antibodies that conferred clinical benefit during the pollen season and supresses pathogenic T cell responses. 31
Study design – RDBCT
Immune mechanisms analyses on participant from a single site - (Ghent, Belgium).
Mechanistic analyses
CSMS
32CSMS during the peak pollen and the entire pollen season
following LPP and Placebo
CSMS –
CSMS – Peak
Peak season
season CSMS – Entire season
Mösges and Shamji, Allergy 2018
333-week treatment with subcutaneous peptide hydrolysates
from Lolium perenne (LPP, gpASIT+TM) supresses CSMS and
RTSS
CSMS RTSS
CSMS reduction in Belgium RTSS reduction in Belgium
Peak period : -35.1%; P=0.03. Peak period: -27.4%, P=0.04
Entire pollen season : -53,7%; P=0.03 Entire pollen season: -56.9%, P=0.01
34 Shamji MH et al, EAACI 2017Hypotheses - 3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne (LPP, gpASIT+TM) is associated with reduction in CSMS and RTSS during the peak and throughout the entire pollen season. - gpASIT+TM immunotherapy but not placebo blunts the seasonal increases of sIgE - gpASIT+TM immunotherapy but not placebo treatment suppresses grass pollen- induced basophil hyperesponsivess and basophil reactivity. - A short-course of gpASIT+TM immunotherapy induces IgG4-associated blocking antibodies that conferred clinical benefit during the pollen season and supresses pathogenic T cell responses. 35
Hypotheses - 3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne (LPP, gpASIT+TM) is associated with reduction in CSMS and RTSS during the peak and throughout the entire pollen season. - gpASIT+TM immunotherapy but not placebo blunts the seasonal increases of sIgE - gpASIT+TM immunotherapy but not placebo treatment suppresses grass pollen- induced basophil hyperesponsivess and basophil reactivity. - A short-course of gpASIT+TM immunotherapy induces IgG4-associated blocking antibodies that conferred clinical benefit during the pollen season and supresses pathogenic T cell responses. 36
Effect of LPP (gpASIT+TM) immunotherapy on sIgE levels
V8-V6
V2 = Before treatment
V6 = After treatment
V8 = After the grass pollen season
37 Shamji MH et al, EAACI 2017Effect of LPP (gpASIT+TM) immunotherapy on sIgE levels
V8-V6
V2 = Before treatment
V6 = After treatment
V8 = After the grass pollen season
38 Shamji MH et al, EAACI 2017Hypotheses - 3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne (LPP, gpASIT+TM) is associated with reduction in CSMS and RTSS during the peak and throughout the entire pollen season. - gpASIT+TM immunotherapy but not placebo blunts the seasonal increases of sIgE - gpASIT+TM immunotherapy but not placebo treatment suppresses grass pollen- induced basophil hyperesponsivess and basophil reactivity. - A short-course of gpASIT+TM immunotherapy induces IgG4-associated blocking antibodies that conferred clinical benefit during the pollen season and supresses pathogenic T cell responses. 39
Hypotheses - 3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne (LPP, gpASIT+TM) is associated with reduction in CSMS and RTSS during the peak and throughout the entire pollen season. - gpASIT+TM immunotherapy but not placebo blunts the seasonal increases of sIgE - gpASIT+TM immunotherapy but not placebo treatment suppresses grass pollen-induced basophil hyperesponsivess and basophil reactivity. - A short-course of gpASIT+TM immunotherapy induces IgG4-associated blocking antibodies that conferred clinical benefit during the pollen season and supresses pathogenic T cell responses. 40
Effect of gpASIT+TM and Placebo on CD203chighCRTH2+
Basophils
* ** * ** **
* *
* *
41 Shamji MH et al, EAACI 2017Hypotheses - 3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne (LPP, gpASIT+TM) is associated with reduction in CSMS and RTSS during the peak and throughout the entire pollen season. - gpASIT+TM immunotherapy but not placebo blunts the seasonal increases of sIgE - gpASIT+TM immunotherapy but not placebo treatment suppresses grass pollen-induced basophil hyperesponsivess and basophil reactivity. - A short-course of gpASIT+TM immunotherapy induces IgG4-associated blocking antibodies that conferred clinical benefit during the pollen season and supresses pathogenic T cell responses. 42
Hypotheses - 3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne (LPP, gpASIT+TM) is associated with reduction in CSMS and RTSS during the peak and throughout the entire pollen season. - gpASIT+TM immunotherapy but not placebo blunts the seasonal increases of sIgE - gpASIT+TM immunotherapy but not placebo treatment suppresses grass pollen- induced basophil hyperesponsivess and basophil reactivity. - A short-course of gpASIT+TM immunotherapy induces IgG4-associated blocking antibodies that conferred clinical benefit during the pollen season and supresses pathogenic T cell responses. 43
Induction of Blocking antibodies following gpASIT+TM and Placebo
Phleum Pratense Lolium Perenne
* *
44 Shamji MH et al, EAACI 2017Induction of blocking antibodies is associated with the induction
of regulatory B cells in gpASIT+TM treated group.
* * *
*
45 Shamji MH et al, EAACI 2018gpASIT+TM is associated with reduction of IL-4+Tfh cells induction
of IFN-g+ Tfh cells and FoxP3+ Tfh cells
* * * *
* *
46 Sharif and Shamji MH et al, AAAAI 2017Summary/Conclusions - 3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne (LPP, gpASIT+TM) is associated with reduction in CSMS and RTSS during the peak and throughout the entire pollen season. - gpASIT+TM immunotherapy but not placebo blunts the seasonal increases of sIgE - gpASIT+TM immunotherapy but not placebo treatment suppresses grass pollen- induced basophil hyperesponsivess and basophil reactivity. - A short-course of gpASIT+TM immunotherapy induces IgG4-associated blocking antibodies that conferred clinical benefit during the pollen season and supresses pathogenic T cell responses. 47
Proposed Mechanisms of gpASIT+TM
ILC2
Natural exposure Cell CRTH2+ T cells
(Low-dose allergen) Allergen-
Th2 IL-9 Mast Cell Basophil specific IgE
Cell
Th IL-5
0
Tfh
Cell Eosinophi
Dendritic cells IL-4 l Plasma Cell
(nasal CXCR5+ T cells IL-21 B
mucosa) IL-13 Cell
Immunotherapy CTL-4 IL-10
(High-dose allergen)
Th Tfr
0 cell
Plasma Cell
IL-27 IL-10/IL-35 Bregs Allergen-specific
iTreg IgG4 & IgA
Dendritic cells IL-10+ TGF-β cell
(under skin or oral
mucosa) Th iTre nTre
1 g +
TGF-β g +
Foxp3
Cel
l
IFN-γ IgG4 and IgA
competes with
IgE for allergen
binding
48 Shamji MH et al, JACI 2017Acknowledgments
Ralph Mösges, MD, PhD,
Elena M. Kasche, MD,
Stephen Durham, MD.FRCP Esther Raskopf, PhD,
Oleksandra (Sasha) Fedina, Jaswinder Singh, MSc,
Lea Sohlich
Angeliki Karamani, BSc Anatoli Astvatsatourov, PhDa, Kija
Rebecca Parkin, BSc Shah-Hosseini
Aliya Datoo
Iesha Singh, MSc
Lubna Kousar, PhD
Hanisah Sharif, MSc Jean Ceupens, MD
Abigail Rob, Bsc Peter Helings, MD, Ludo Haazen, MD
Sabine Pirotton, PhD
Nathalie Wathelet, PhD
Marie-Alix Bonny
Nicolas Bovy, PhD
Claus Bachert, MD, PhD
Julie Halkein, PhD
Philip Gaevert, MD, PhD
Valeria Karusinova
Lara Derycke, MD
Gael Placier, PhD
Gabrielle Holtapples, MSc
Jean Duchateau, MD, PhD
Thierry Legon, MBA
49hdm-ASIT+™ for house dust mite rhinitis
first in man clinical study: safety of ASIT+TM confirmed
TRIAL # PATIENTS AIM COMPLETED
‒ Assessment of the maximum tolerated ‒ Q2 2017
‒ 36 patients randomized
dose
Phase I/IIa
‒ Safety and clinical tolerability
‒ Immunogenicity
‒ Impact on reactivity to a challenge test
• 27 patients treated with hdm-ASIT+™ - 9 placebo.
• safety and tolerability of hdm-ASIT+™ confirmed
• slight positive immunological and clinical impact in a limited number of treated patients
• new product prototypes in development to be tested by Prof. M. Shamji at ICL to optimize the product candidates
immunogenicity
50food-ASIT+™ for food allergy
product prototypes screening on-going
PRE-CLINICAL DEVELOPMENT AIM COMPLETED
‒ Selection of product candidate
Product peanut, cow’s milk & egg white ‒ Q2 2018
prototype ex
vivo screening
‒ ex vivo safety and tolerability
‒ ex vivo immunogenicity
• non-dilutive funding from the Walloon Region to co-finance 55% 1
• collaboration with Prof. M. Shamji (ICL), and Dr. S. Till (King’s)
• first-in-man Phase I/II trial in peanut allergy expected to be conducted from H1 2018 to end-2019
1 a recoverable cash advance granted in January 2017
51ASIT biotech pipeline: next milestones
Pre-clinical Phase I Phase II Phase III
gp-ASIT+™ FDA meeting - H2 2018
Grass pollen Second Phase III Q4 2018 - Q4 2019
Selection of a new ASIT+TM active ingredient - Q2 2018
hdm-ASIT+™ Second Phase I/II clinical trial with improved prototype - Q1 2019
House dust mite
food-ASIT+™ Selection of ASIT+TM active ingredient for peanut - Q2 2018
Food First Phase I/II clinical trial in food - H2 2018
Peanut - Egg white - Cow’s milk
52Summary 53
Short course immunotherapy with ASIT biotech’s
allergenic peptides addresses the unmet needs of
all stakeholders
4 visits/year
Patient Healthcare systems Allergists
• Efficient: Reduction of • Documented safety and • New therapeutic option
symptoms and rescue efficacy • More patient accepting AIT
medication in the real life &
• Improved acceptance • Patients more compliant
Improved quality of life
• Improved compliance • Fast onset of action
• 4 doctor visits
• Improved real-life efficacy • Better patient follow-up
• Time & Money saving
• Reduced direct & indirect costs • Higher patient satisfaction
54Paris May 03 2018 Leader in Allergenic Peptide Immunotherapy
Merci pour votre attention !
55Disclaimer
• THIS DOCUMENT AND ANY MATERIALS DISTRIBUTED IN CONNECTION WITH THIS DOCUMENT ARE NOT DIRECTED TO, OR INTENDED FOR DISTRIBUTION TO OR USE BY,
ANY PERSON OR ENTITY THAT IS A CITIZEN OR RESIDENT OR LOCATED IN ANY LOCALITY, STATE, COUNTRY OR OTHER JURISDICTION WHERE SUCH DISTRIBUTION,
PUBLICATION, AVAILABILITY OR USE WOULD BE CONTRARY TO LAW OR REGULATION OR WHICH WOULD REQUIRE ANY REGISTRATION OR LICENSING WITHIN SUCH
JURISDICTION. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAW AND PERSONS INTO WHOSE POSSESSION THIS
DOCUMENT COMES SHOULD INFORM THEMSELVES ABOUT, AND OBSERVE ANY SUCH RESTRICTIONS.
• This presentation has been prepared by the management of ASIT biotech SA (the Company). It does not constitute or form part of, and should not be construed as,
an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company nor should it or any part of it form the basis of, or be
relied on in connection with, any contract to purchase or subscribe for any securities of the Company, nor shall it or any part of it form the basis of or be relied on in
connection with any contract or commitment whatsoever.
• This presentation is not a prospectus and recipients should not purchase, subscribe for or otherwise acquire any securities of the Company except on the basis of
information in a prospectus or in the annual report approved by the FSMA. Copies of the prospectus and annual report issued are available on the website of the
Company or at the Company’s registered office.
• The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and
amendment and such information may change materially. No person is under any obligation to update or keep current the information contained in this presentation
and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness,
accuracy, reasonableness or completeness of the information contained herein. Neither the Company nor any other person accepts any liability for any loss
howsoever arising, directly or indirectly, from this presentation or its contents.
• This presentation includes forward-looking statements that reflect the Company's intentions, beliefs or current expectations concerning, among other things, the
Company’s results, condition, performance, prospects, growth, strategies and the industry in which the Company operates. These forward-looking statements are
subject to risks, uncertainties and assumptions and other factors that could cause the Company's actual results, condition, performance, prospects, growth or
opportunities, as well as those of the markets it serves or intends to serve, to differ materially from those expressed in, or suggested by, these forward-looking
statements. The Company cautions you that forward-looking statements are not guarantees of future performance and that its actual results and condition and the
development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements contained in this
presentation. In addition, even if the Company's results, condition, and growth and the development of the industry in which the Company operates are consistent with
the forward-looking statements contained in this presentation, those results or developments may not be indicative of results or developments in future periods. The
Company and each of its directors, officers and employees expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to
any forward-looking statements in this presentation or any change in the Company's expectations or any change in events, conditions or circumstances on which
these forward-looking statements are based, except as required by applicable law or regulation.
• In this presentation, references are made to the Company’s product candidates, for which marketing authorisation has not yet been obtained. These product
candidates are designated throughout this presentation by their internal project names at the Company. The names used are not meant to refer to these products (if
and when they will be approved), as it is yet uncertain if and under what names these product candidates would be marketed in the future. Nothing in this presentation
should be construed as endorsing or advertising such product candidates.
56CONTACTS
ASIT Biotech
Thierry Legon – CEO
Tel.: +32 2 264 03 90
investors@asitbiotech.com
www.asitbiotech.com
57You can also read
